A study led by Dana-Farber Cancer Institute researchers found that combining chemotherapy and immunotherapy before surgery ...

Small cell lung cancer is aggressive and spreads quickly. There are many options for treatment, depending on the type and stage of SCLC.

The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a ...

Data from the DeLLphi-304 trial “clearly support tarlatamab as a preferable therapy” for SCLC in the second-line setting, said Charles M. Rudin, MD, PhD.

The FDA has granted accelerated approval to datopotamab deruxtecan (Datroway) for adults with locally advanced or metastatic non-small cell lung cancer that carries an EGFR mutation and has progressed ...

Non-small-cell lung cancer (NSCLC) is the most common type of cancer affecting the lungs. The diverse types of NSCLC are characterized by cancer cells that grow and spread in different ways.

This article explores how cancer biomarkers improve early detection, guide treatments and predict outcomes to transform ...

Lung cancer is a big problem. It claims many lives each year. Around 160,000 people die annually in the US. This figure is ...

In May 2025, the Journal for ImmunoTherapy of Cancer published a pioneering study entitled "NeoPred: dual-phase CT AI forecasts pathologic response to ...

Lung cancer proved the second-most discussed cancer type during ASCO 2025, totalling 2,995 mentions by more than 530 HCPs. As ...

Cancer is a disease where abnormal cells grow uncontrollably and can invade other parts of the body. One of the most ...